Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes - Trial NCT03136484
Access comprehensive clinical trial information for NCT03136484 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 788 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novo Nordisk A/S
Timeline & Enrollment
Phase 3
Mar 15, 2017
Nov 16, 2018
Primary Outcome
Change in HbA1c
Summary
This trial is conducted in Africa, Asia, Europe, North and South America. The aim of the
 trial is to compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0
 mg) versus once-daily dosing of oral canagliflozin (300 mg) on glycaemic control in subjects
 with type 2 diabetes (T2D) on a background treatment of metformin
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03136484
Non-Device Trial